Checked
GLAUKOS Corp
NYSE: GKOS · Surgical & Medical Instruments & Apparatus · Aliso Viejo, CA
- Revenue
- $507.4M
- +32.3% vs. prior year
- Net income
- -$187.7M
- -37.0% net margin
- Total assets
- $893.5M
- Diluted EPS
- -$3.28
Company details
As reported to the SEC
- SEC CIK
- 1192448
- Stock
- NYSE: GKOS
- Legal Entity Identifier (LEI)
- 5299004JA1LHE21M6T14
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus (3841)
- Headquarters
- 1 Glaukos Way, Aliso Viejo, CA 92656
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Phone
- (949) 367-9600
- Last annual report
- 02/23/2026
- Last quarterly report
- 07/29/2026
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $507.4M | $383.5M | $314.7M | $282.9M | $294M |
| Gross profit | $282.8M | $289.5M | $239.1M | $213.9M | $227.4M |
| Operating income | -$199.6M | -$122.4M | -$128.7M | -$82.31M | -$32.87M |
| Net income | -$187.7M | -$146.4M | -$134.7M | -$99.19M | -$49.59M |
| Diluted earnings per share | -$3.28 | -$2.77 | -$2.78 | -$2.09 | -$1.07 |
| Research and development | $150.6M | $136.4M | $138.8M | $123.3M | $101M |
| Total assets | $893.5M | $974.8M | $940.4M | $1B | $1.05B |
| Total liabilities | $237.3M | $207.8M | $478.6M | $472.4M | $462.5M |
| Shareholders' equity | $656.2M | $766.9M | $461.8M | $530M | $587.2M |
| Cash and cash equivalents | $90.81M | $169.6M | $93.47M | $119.5M | $100.7M |
| Cash from operations | -$14.79M | -$61.32M | -$57.76M | -$33.08M | $24.71M |
| Capital expenditures | $7.67M | $6.3M | $20.25M | $30.27M | $47.78M |
Federal and state records filed under the name GLAUKOS Corp
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Glaukos CorporationAliso Viejo, CA | 7 | 0 |
| Avedro, Inc.Subsidiary · Burlington, MA | 3 | 1 |
Drug shortages
Products this company makes or markets that are on the FDA drug shortage list
| Drug | Status |
|---|---|
| Riboflavin 5-phosphate Ophthalmic Solution | To Be Discontinued |
Subsidiaries
18 companies that GLAUKOS Corp owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Avedro, Inc. | SEC 10-K |
| GKOS Medical, Unipessoal LDA | SEC 10-K |
| Glaukos (Switzerland) AG | SEC 10-K |
| Glaukos Acquisition Corp. | SEC 10-K |
| Glaukos Australia Pty Ltd | SEC 10-K |
| Glaukos Belgium | SEC 10-K |
| Glaukos Canada Inc. | SEC 10-K |
| Glaukos France SAS | SEC 10-K |
| Glaukos Germany GmbH | SEC 10-K |
| Glaukos Ireland Limited | SEC 10-K |
| Glaukos Japan GK | SEC 10-K |
| Glaukos Medical Spain, S.L. | SEC 10-K |
| Glaukos Netherlands B.V. | SEC 10-K |
| Glaukos Norway AS | SEC 10-K |
| Glaukos Produtos M dicos Ltda. | SEC 10-K |
| Glaukos Singapore PTE. LTD. | SEC 10-K |
| Glaukos Sweden AB | SEC 10-K |
| Glaukos UK Limited | SEC 10-K |
Recent filings
126 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
116 insider ownership reports (Forms 3, 4, 5 and 144) were filed about GLAUKOS Corp in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other surgical & medical instruments & apparatus
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Medline Inc.MDLN | Northfield, IL | $28.43B | $1.16B |
| Stryker CorpSYK | Portage, MI | $25.12B | $3.25B |
| 3m CoMMM | St Paul, MN | $24.95B | $3.25B |
| Becton Dickinson & CoBDX | Franklin Lakes, NJ | $21.84B | $1.68B |
| Boston Scientific CorpBSX | Marlborough, MA | $20.07B | $2.89B |
| Baxter International IncBAX | Deerfield, IL | $11.24B | -$957M |
| Solventum CorpSOLV | Eagan, MN | $8.32B | $1.56B |
| Resmed IncRMD | San Diego, CA | $5.65B | $1.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is GLAUKOS Corp's CIK number?
- GLAUKOS Corp's SEC Central Index Key (CIK) is 1192448.
- What is GLAUKOS Corp's stock ticker?
- GLAUKOS Corp trades as NYSE: GKOS.
- What was GLAUKOS Corp's revenue?
- GLAUKOS Corp reported revenue of $507.4M for the fiscal year ended Dec 31, 2025, +32.3% from the year before.
- When does GLAUKOS Corp's fiscal year end?
- GLAUKOS Corp's fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is GLAUKOS Corp headquartered?
- GLAUKOS Corp's principal executive office on file with the SEC is in Aliso Viejo, CA.
- What companies does GLAUKOS Corp own?
- GLAUKOS Corp lists 18 subsidiaries in its SEC filings and other public records, including Avedro, Inc., GKOS Medical, Unipessoal LDA, Glaukos (Switzerland) AG.
- Does GLAUKOS Corp sponsor H-1B visas?
- Department of Labor records show 10 certified H-1B filings and 1 certified PERM filings under the name GLAUKOS Corp.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026